Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control study
about
High density lipoprotein and metabolic disease: Potential benefits of restoring its functional propertiesSoy-based renoprotectionHDL and glucose metabolism: current evidence and therapeutic potentialCardiovascular complications of type 1 diabetes: update on the renal link.Epidemiology of cardiovascular disease: recent novel outlooks on risk factors and clinical approaches.Serum Concentration of HDL Particles Predicts Mortality in Acute Heart Failure Patients.Serum FABP5 concentration is a potential biomarker for residual risk of atherosclerosis in relation to cholesterol efflux from macrophagesReduced HDL function in children and young adults with type 1 diabetes.Metrics of High-Density Lipoprotein Function and Hospital Mortality in Acute Heart Failure PatientsSerum levels of mitochondrial inhibitory factor 1 are independently associated with long-term prognosis in coronary artery disease: the GENES StudyABCA1 agonist peptides for the treatment of disease.Proteomic analysis of HDL from inbred mouse strains implicates APOE associated with HDL in reduced cholesterol efflux capacity via the ABCA1 pathwayNiacin Therapy Increases High-Density Lipoprotein Particles and Total Cholesterol Efflux Capacity But Not ABCA1-Specific Cholesterol Efflux in Statin-Treated Subjects.LXR Agonism Upregulates the Macrophage ABCA1/Syntrophin Protein Complex That Can Bind ApoA-I and Stabilized ABCA1 Protein, but Complex Loss Does Not Inhibit Lipid Efflux.Beyond Coronary Calcification, Family History, and C-Reactive Protein: Cholesterol Efflux Capacity and Cardiovascular Risk PredictionImpaired HDL cholesterol efflux in metabolic syndrome is unrelated to glucose tolerance status: the CODAM study.A single infusion of MDCO-216 (ApoA-1 Milano/POPC) increases ABCA1-mediated cholesterol efflux and pre-beta 1 HDL in healthy volunteers and patients with stable coronary artery disease.Patients With Coronary Endothelial Dysfunction Have Impaired Cholesterol Efflux Capacity and Reduced HDL Particle Concentration.High-Density Lipoproteins, Endothelial Function, and Mendelian Randomization.HDAC9 Variant Rs2107595 Modifies Susceptibility to Coronary Artery Disease and the Severity of Coronary Atherosclerosis in a Chinese Han Population.The therapeutic efficacy of intensive medical therapy in ameliorating high-density lipoprotein dysfunction in subjects with type two diabetes.Enhanced HDL Functionality in Small HDL Species Produced Upon Remodeling of HDL by Reconstituted HDL, CSL112: Effects on Cholesterol Efflux, Anti-Inflammatory and Antioxidative Activity.Different relationship between ANGPTL3 and HDL components in female non-diabetic subjects and type-2 diabetic patients.Cholesterol Efflux Capacity of Apolipoprotein A-I Varies with the Extent of Differentiation and Foam Cell Formation of THP-1 Cells.Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction: The AEGIS-I Trial (ApoA-I Event Reducing in Ischemic Syndromes I).Maternal Circulating Lipid Profile during Early Pregnancy: Racial/Ethnic Differences and Association with Spontaneous Preterm Delivery.Apolipoprotein B-containing lipoproteins and atherosclerotic cardiovascular disease.Cholesterol Efflux Capacity, High-Density Lipoprotein Particle Number, and Incident Cardiovascular Events: An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin).Dysfunctional HDL and atherosclerotic cardiovascular disease.New and emerging biomarkers in cardiovascular disease.Kidneys: key modulators of high-density lipoprotein levels and function.Bilirubin Decreases Macrophage Cholesterol Efflux and ATP-Binding Cassette Transporter A1 Protein Expression.Influence of HDL particles on cell-cholesterol efflux under various pathological conditions.Cholesteryl ester transfer protein inhibitors: challenges and perspectives.Future Lipid-Altering Therapeutic Options Targeting Residual Cardiovascular Risk.Bolstering cholesteryl ester hydrolysis in liver: A hepatocyte-targeting gene delivery strategy for potential alleviation of atherosclerosis.Genetics of Lipid and Lipoprotein Disorders and Traits.A novel approach to measuring macrophage-specific reverse cholesterol transport in vivo in humans.Inflammation, remodeling, and other factors affecting HDL cholesterol efflux.Evaluating bempedoic acid for the treatment of hyperlipidaemia.
P2860
Q26750603-4F6FB4A7-4CAE-4AB7-899F-1708F3C30061Q26751544-507ED5E1-E4DE-47E9-905C-73C19AA8FF00Q26996502-BDED7F29-31C1-468A-AE79-666D0F6A3FEEQ30239971-993543D0-17B4-45E8-93DE-F02CBC6F905DQ30251632-B12B2E03-22BD-4AB5-9CAE-EB0D741B4EE3Q33572720-274D5094-4FEF-42D8-9A4D-1DC4EEB8930DQ33669547-882049C9-39D8-49D5-87A6-4E946963AB81Q33882594-9C7CDD75-8FE8-45E2-83AD-B728B1101849Q36052803-8F229F10-EBED-4E62-86CA-061C0E16028FQ36110734-6FBCF10B-4597-4F98-9050-0322DDF6C4DAQ36436785-44390292-5216-4EF0-ADF1-36658FFA6BC5Q36503826-5C320A8D-C77A-4403-8F0C-E29C9D2A4EEBQ36560360-411E38D8-14E5-4BA1-A579-A3B334DAA8A0Q36920544-D5731348-2E10-41E4-8AB3-275218822C20Q36945110-725D4D65-3A00-4E6D-A72E-6E1479FD9970Q36980202-2ED5BD51-C141-4591-8EDC-6EDF280AB177Q36988873-B42E7687-7C3F-4779-9EE2-E802C551455DQ37037342-1A983E4D-64DA-4EC1-BFAD-7B68BA1BB72EQ37041783-079CD32F-2EEB-4E01-AB25-CB22E895F33DQ37155689-60B92BA2-5587-43E3-BF2B-558572173A9DQ37211868-4A1E6D0C-0E73-469C-B928-69E4CBC17CE3Q37221857-2AD95D18-08FE-42CB-B0CA-95715FBB01DDQ37251396-03F52763-B75B-41C5-8B2E-DE7E98FDFA99Q37430678-94D1DE1E-BFEC-4201-9833-13C7252DA88BQ37488452-F26F61F1-2DEE-4429-A70A-3D8B2286A89BQ37628335-E598A81F-8C0B-46D5-B54E-E8633CB29497Q37643353-2009C125-2612-443E-ABCE-B9D32F35AECDQ38377434-4078008F-387B-42DA-8441-52967E1E24D6Q38577283-B9734A93-41FD-432A-9451-01AC1D897963Q38586900-5AF07DA3-8652-4910-BB9A-56F98ED45332Q38786424-598CB6F7-3EB1-4A1A-A443-32E740CCA146Q38813542-A9A7729E-728B-463D-A071-9D8CC5C1C2F0Q38831490-D65903F1-A59F-4D87-9129-4235E45F4969Q38832774-EFDE0055-A763-47E6-BCC5-0CD56C2AF7F1Q38842531-4597FD1D-4051-4216-99DD-684D4713EF1FQ38871582-EC1231FD-A6EF-4D54-A8B2-D76D2A0D933CQ38911979-8DBDB668-0595-4B9A-8DDB-20E5BB132FEDQ38975380-C84D0F19-E688-4659-8162-1F86025E9435Q39025753-C771E5C0-2055-490C-AB34-90E34C3BD8A3Q39074339-CCC0727A-504B-4FF1-96A1-276AFB3F2E77
P2860
Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control study
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Association of HDL cholesterol ...... prospective case-control study
@ast
Association of HDL cholesterol ...... prospective case-control study
@en
type
label
Association of HDL cholesterol ...... prospective case-control study
@ast
Association of HDL cholesterol ...... prospective case-control study
@en
prefLabel
Association of HDL cholesterol ...... prospective case-control study
@ast
Association of HDL cholesterol ...... prospective case-control study
@en
P2093
P2860
P50
P1476
Association of HDL cholesterol ...... prospective case-control study
@en
P2093
Amrith Rodrigues
Antonino Picataggi
Daniel J Rader
Daniya Lukmanova
Jeffery Billheimer
John J P Kastelein
Megan L Mucksavage
Nick Wareham
Robert Scott
S Matthijs Boekholdt
P2860
P304
P356
10.1016/S2213-8587(15)00126-6
P577
2015-05-27T00:00:00Z